Member Info for Timster

Fairly obvious what generaloz was up to when he started initially posting positively.

Confusing but these are key dates in the RNS:

AVA6000:

o Read out of two-weekly and three-weekly dose escalation study data in late Q2 2024;

o Presentation of Phase 1 three-weekly study clinical data at AACR 2024 in April 2024; and

o Establish recommended Phase 2 dose in Q3 2024, initiating the dose expansion phase in the US in H2 2024, followed by the Phase 2 study, subject to funding and FDA approval.

PJT

10 tumour biopsies obtained from 9 patients in different cohorts have also been analysed in order to confirm the release of the active chemotherapy, doxorubicin, in the tumour tissue. This analysis shows that AVA6000 targets the release of doxorubicin to the tumour tissue at therapeutic levels which are much higher than the levels being detected in the bloodstream at the same time point.

Pharmacokinetic data indicate that systemic levels of doxorubicin are considerably lower compared to standard 75mg/m2 doxorubicin dosing, potentially allowing for higher dosing or more treatment cycles.

a 59-year-old male with the diagnosis of undifferentiated pleomorphic sarcoma, treated at 160 mg/m2 on a three-weekly dosing ("q3w"), resulted in a partial response with a duration of greater than 6 months and a tumour volume reduction of ~65%. treatment is ongoing, with high fap expression observed in the tumour tissue and a favourable pk profile with reduction in auc which permits dosing for 7 additional cycles (~21 weeks); and

· a 79-year-old female with the diagnosis of angiosarcoma of the spleen has been treated at 250 mg/m2 q3w, with minor response with visceral (hepatic) metastases resulting in a reduction of 14% at cycle 2 and ~22% at cycle 4, with a continued shrinkage of liver metastases at cycle 4 scan, with interval development of new bone metastases (mixed response).

i remain invested if avacta can bring to market it's huge and of a massive benefit to sufferers of this awful disease.

this placing is a **** show that is not in doubt.

Cohort 7, at a dose of 385mg/m2 (equivalent to approximately 3.5 times the normal dose of doxorubicin), has not shown to date the typical drug-related cardiotoxicity and pharmacokinetic data suggest that AVA6000 has the potential to be used for 2-3 times more cycles (depending on dose) than standard 75mg/m2 doxorubicin dosing.

It's £200 ex chi-nah

agreed pre|cision works as intended.

high levels of dox released directly into the tumour.

al is still **** though.

Needs a hard kick in the balls

Guess you've been selling them having access to this inside info?

You've gone down .9% in certainty. What's happened ?

What happens now, golden death cross?

It's the translation don't panic

Obviously the usual three disruptive trolls still here today. But the rest of the new accounts appear to have given up and moved on.

Two months in post now, deals do take time. But I hardly think his first major achievement will be a 60p placing.

"Simon has over 26 years' commercial experience in the biopharma industry. He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America."

Sujood is the only one who knows what's happening.

Can't wait till November 21st...

which would suggest one of two things.

1. he doesn't give two ****s about shareholders and current share price.

2. he can't release anything at the moment as something else is going on.

here's the lull while the cage of twats have their morning meeting. what new attack plan will come out with??

i'm going to say another day with exactly the same made up ******.

I expect they are waiting till 20p to raise.

Are we back to pre|CISION not working again?

It works.... Ignore the twats read the facts

"If the company finds a funding solution higher than the current price (75p), you can patronise me all you want."

You'll be long gone along with all the other twats